Pooled analysis of mid-regional pro-adrenomedullin values in COVID-19 patients with critical illness

[1]  F. Bassi,et al.  MR-proADM as prognostic factor of outcome in COVID-19 patients , 2021, Scientific Reports.

[2]  D. Spinelli,et al.  High levels of mid-regional proadrenomedullin in ARDS COVID-19 patients: the experience of a single, Italian Center. , 2021, European review for medical and pharmacological sciences.

[3]  P. Schuetz,et al.  The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study , 2021, Clinical chemistry and laboratory medicine.

[4]  V. Fanelli,et al.  Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study , 2020, PloS one.

[5]  F. Agrò,et al.  High value of mid‐regional proadrenomedullin in COVID‐19: A marker of widespread endothelial damage, disease severity, and mortality , 2020, Journal of medical virology.

[6]  L. Maier,et al.  RNA-expression of adrenomedullin is increased in patients with severe COVID-19 , 2020, Critical Care.

[7]  G. Lippi,et al.  COVID-19: unravelling the clinical progression of nature’s virtually perfect biological weapon , 2020, Annals of translational medicine.

[8]  Wenhong Zhang,et al.  Risks and features of secondary infections in severe and critical ill COVID-19 patients , 2020, Emerging microbes & infections.

[9]  D. Popov,et al.  Predictive value of proadrenomedullin in patients with COVID-19 , 2020 .

[10]  J. Rello,et al.  Mid-Regional Pro-Adrenomedullin (MR-proADM) as a Biomarker for Sepsis and Septic Shock: Narrative Review , 2018, Healthcare.

[11]  J. F. Rodríguez-Gutiérrez,et al.  New role of biomarkers: mid-regional pro-adrenomedullin, the biomarker of organ failure. , 2016, Annals of translational medicine.

[12]  Lixin Xie,et al.  Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis , 2016, BMC Infectious Diseases.

[13]  M. Ruiz,et al.  Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology , 2011, European Respiratory Journal.

[14]  I. Hozo,et al.  Estimating the mean and variance from the median, range, and the size of a sample , 2005, BMC medical research methodology.